Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging Phase 2 Study of JNJ-64565111 in Non-diabetic Severely Obese Subjects
2017-003616-39Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efinopegdutide in obesity (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Primary efficacy endpoint and Safety and tolerability. Started Mar 2018; status: completed.
02
Drugs
efinopegdutide
03
Conditions
obesity
Beyond the preview
Go deeper on 2017-003616-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003616-39.